Revista de la Sociedad Argentina de Diabetes
Estrategias de tratamiento en personas con diabetes
By Susana Fuentes.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over 80% of patients with type 2 diabetes (T2D) in Argentina, demanding a comprehensive clinical approach to prevent progression to cirrhosis. The cornerstone of treatment remains intensive lifestyle modification; achieving a weight loss of 5% to 10% effectively reduces steatosis, while a reduction greater than 10% achieves fibrosis regression and steatohepatitis (MASH) resolution. Specific hepatic pharmacotherapy is indicated for patients with MASH and clinically significant fibrosis (F2). In individuals with T2D, the use of GLP-1 receptor agonists (like semaglutide) is strongly prioritized, as they have been shown to resolve steatohepatitis, improve fibrosis, and significantly reduce cardiovascular events. Meanwhile, resmetirom (a selective THR- agonist) is approved for non-cirrhotic MASH with F2-F3 fibrosis, representing the preferred option if the patient is already receiving a GLP-1 RA for underlying obesity or diabetes. Additionally, SGLT2 inhibitors remain essential adjuncts for glycemic control and cardio-renal protection in these patients.
Keywords
- Liver Disease Diagnosis and Treatment
- Open access
Source
Published in Revista de la Sociedad Argentina de Diabetes. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.
